Agendia Demonstrates MammaPrint Utility in Predicting Chemotherapy Benefit Over 5 Years in Patients with HR+HER2- Early Breast Cancer at SABCS 2024

New data reinforces findings from MINDACT supporting MammaPrintยฎ in Read More

2024-12-11T15:26:18-05:00December 11th, 2024|Press Releases|

Agendia Announces Publication Validating MammaPrint Utility in Prediction of Extended Endocrine Therapy Benefit

A secondary analysis of the randomized controlled trial, IDEAL, Read More

2024-12-02T12:21:50-05:00December 2nd, 2024|Press Releases|

Agendia to Unveil New Findings in Early-Stage Breast Cancer at San Antonio Breast Cancer Symposium 2024

New data reinforces MammaPrintยฎ and BluePrintยฎ testsโ€™ expanding clinical Read More

2024-11-21T15:36:37-05:00November 25th, 2024|Press Releases|

Agendia Co-Founder Prof. Dr. Laura vanโ€™t Veer Honored at Three Prestigious Breast Cancer Symposia in Italy, the Netherlands and the U.S. for Pioneering Work in Breast Cancer Diagnostics

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS, November 14, 2024 Read More

2024-11-22T12:52:37-05:00November 14th, 2024|Press Releases|

Agendia’s FLEX Study Reaches Enrollment of Over 17,000 Early-Stage Breast Cancer Patients Across Diverse Population

This achievement highlights the remarkable seven-year progression of FLEX Read More

2024-09-09T13:12:29-04:00September 12th, 2024|Press Releases|

MammaPrint & 3-year outcome of CT with/without anthracycline-ASCO 2024

Association of MammaPrint index and 3-year outcome of patients in the FLEX Registry trial with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline

Read More
2024-08-05T13:02:51-04:00May 31st, 2024|Press Releases|
Go to Top